Jürgen Weitz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jürgen Weitz has a total of 235 co-authors. Here are the top co-authors by number of shared publications:
- Markus Wolfgang Büchler
Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany
16 shared publications - Moritz Koch
Department of Surgery, University of Heidelberg, Heidelberg, Germany
16 shared publications Moritz Koch
University of Heidelberg
14 shared publicationsMarkus W. Büchler
Department of General, Visceral and Transplant Surgery, University Hospital Heidelberg, Germany
12 shared publications- Nuh N. Rahbari
Department of Surgery, University of Heidelberg, Heidelberg, Germany
9 shared publications - Christoph Reissfelder
Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany; Department of Visceral, Thoracic and Vascular Surgery, University of Dresden, Dresden, Germany
7 shared publications
Latest Publications
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Tu1841 - Tgf-β1 Selectively Induces Segmental Fibrosis Upon Activation by Cre Recombination in a Novel Animal Model for Crohn's Disease
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Tu1841 - Tgf-β1 Selectively Induces Segmental Fibrosis Upon Activation by Cre Recombination in a Novel Animal Model for Crohn's Disease
- 28 October 2017
- Published by Springer Nature
- p. 371-375
Surgical Technique and Difficult Situations from Juergen Weitz (Conventional)
- 28 October 2017
- Published by Springer Nature
- p. 371-375
Surgical Technique and Difficult Situations from Juergen Weitz (Conventional)
- 29 June 2017
- Published by Georg Thieme Verlag KG in Gastroenterologie up2date
- Vol. 13 (02) , 159-174
Tumoren der Papille und des Duodenums
Die Tumoren der Papille und des Duodenums umfassen eine heterogene Gruppe verschiedener gut- oder bösartiger Entitäten – mit entsprechend unterschiedlicher Anamnese, Symptomatik, multimodaler Diagnostik (Endoskopie, nichtinvasive Bildgebung) und Therapie. Die chirurgische Therapie ist anspruchsvoll, oft mit einer relevanten Morbidität assoziiert und erfordert eine hohe Expertise der primären Versorgung, aber auch des Komplikationsmanagements.
- 29 June 2017
- Published by Georg Thieme Verlag KG in Gastroenterologie up2date
- Vol. 13 (02) , 159-174
Tumoren der Papille und des Duodenums
Die Tumoren der Papille und des Duodenums umfassen eine heterogene Gruppe verschiedener gut- oder bösartiger Entitäten – mit entsprechend unterschiedlicher Anamnese, Symptomatik, multimodaler Diagnostik (Endoskopie, nichtinvasive Bildgebung) und Therapie. Die chirurgische Therapie ist anspruchsvoll, oft mit einer relevanten Morbidität assoziiert und erfordert eine hohe Expertise der primären Versorgung, aber auch des Komplikationsmanagements.
- 22 February 2016
- Published by Wiley in Journal of Surgical Oncology
- Vol. 113 (6) , 668-671
Top‐down approach to the superior mesenteric artery and the mesopancreas during pancreatoduodenectomy for pancreatic cancer
Complete surgical resection with microscopically tumor-free resection margins (R0) is the most important survival determinant for patients with localized pancreatic cancer. The medial and posterior resection margins are the dominant sites of microscopic tumor involvement, and outline the so-called mesopancreas. In this study, we present a modified surgical approach to the superior mesenteric artery, celiac trunc, and mesopancreas during pancreatoduodenectomy, which enables a comfortable exposure and radical en bloc clearance of the mesopancreas and the tissue adjacent to the superior mesenteric artery. The dissection of the mesopancreas is directed from the ventral aspect of the portal vein downward along the superior mesenteric artery and the celiac trunc, before the transection of the duodenal mesentery is accomplished. The described technique complements the established surgical approaches to pancreatic head tumors, and is indicated in the absence of portal vein infiltration. J. Surg. Oncol. 2016;113:668–671.
- 22 February 2016
- Published by Wiley in Journal of Surgical Oncology
- Vol. 113 (6) , 668-671
Top‐down approach to the superior mesenteric artery and the mesopancreas during pancreatoduodenectomy for pancreatic cancer
Complete surgical resection with microscopically tumor-free resection margins (R0) is the most important survival determinant for patients with localized pancreatic cancer. The medial and posterior resection margins are the dominant sites of microscopic tumor involvement, and outline the so-called mesopancreas. In this study, we present a modified surgical approach to the superior mesenteric artery, celiac trunc, and mesopancreas during pancreatoduodenectomy, which enables a comfortable exposure and radical en bloc clearance of the mesopancreas and the tissue adjacent to the superior mesenteric artery. The dissection of the mesopancreas is directed from the ventral aspect of the portal vein downward along the superior mesenteric artery and the celiac trunc, before the transection of the duodenal mesentery is accomplished. The described technique complements the established surgical approaches to pancreatic head tumors, and is indicated in the absence of portal vein infiltration. J. Surg. Oncol. 2016;113:668–671.
- 15 June 2015
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 221 (3) , 717-728e1
Impact of Neoadjuvant Chemotherapy on Hypertrophy of the Future Liver Remnant after Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy
Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) has been demonstrated as a feasible procedure in extended liver resections as a means of successfully increasing the volume of the future liver remnant (FLR). Neoadjuvant chemotherapy (CTx) is toxic to the organ and may impair hepatic regeneration. This study was performed to assess the procedure's effect on hypertrophy of the FLR, including the short-term survival. We analyzed 19 consecutive ALPPS patients, of whom 58% (n = 11) received neoadjuvant CTx because of colorectal liver metastasis (CRM). Patients presented with multifocal CRM (n = 11, 58%); cholangiocarcinoma (n = 7, 37%), of which 5 were in the Klatskin position; and gallbladder carcinoma (n = 1, 5%). Hepatectomy was performed within 6 to 13 days after hepatic partition. Volumetry was performed before both liver partitioning and hepatectomy. A survival analysis was performed. Liver partition and portal vein ligation induced sufficient hypertrophy of the FLR, with an increased volume of 74% ± 35%. Patients underwent hepatectomy after a median of 8 days; in all cases R0 resection was achieved. Neoadjuvant CTx was shown to significantly impair hypertrophy. The volume of the FLR in non-CTx patients increased by 98% ± 35%; an increase of 59% ± 22% was observed in patients who underwent CTx (p = 0.027). Chemotherapy did not have an impact on either morbidity or in-hospital mortality, which were 68% and 16%, respectively. One-year overall survival was 53%, with a 1-year survival of 67% in CRM patients and 38% in non-CRM patients (p > 0.05). Data presented here demonstrate for the first time that neoadjuvant CTx significantly impairs hypertrophy of the FLR after ALPPS.
- 15 June 2015
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 221 (3) , 717-728e1
Impact of Neoadjuvant Chemotherapy on Hypertrophy of the Future Liver Remnant after Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy
Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) has been demonstrated as a feasible procedure in extended liver resections as a means of successfully increasing the volume of the future liver remnant (FLR). Neoadjuvant chemotherapy (CTx) is toxic to the organ and may impair hepatic regeneration. This study was performed to assess the procedure's effect on hypertrophy of the FLR, including the short-term survival. We analyzed 19 consecutive ALPPS patients, of whom 58% (n = 11) received neoadjuvant CTx because of colorectal liver metastasis (CRM). Patients presented with multifocal CRM (n = 11, 58%); cholangiocarcinoma (n = 7, 37%), of which 5 were in the Klatskin position; and gallbladder carcinoma (n = 1, 5%). Hepatectomy was performed within 6 to 13 days after hepatic partition. Volumetry was performed before both liver partitioning and hepatectomy. A survival analysis was performed. Liver partition and portal vein ligation induced sufficient hypertrophy of the FLR, with an increased volume of 74% ± 35%. Patients underwent hepatectomy after a median of 8 days; in all cases R0 resection was achieved. Neoadjuvant CTx was shown to significantly impair hypertrophy. The volume of the FLR in non-CTx patients increased by 98% ± 35%; an increase of 59% ± 22% was observed in patients who underwent CTx (p = 0.027). Chemotherapy did not have an impact on either morbidity or in-hospital mortality, which were 68% and 16%, respectively. One-year overall survival was 53%, with a 1-year survival of 67% in CRM patients and 38% in non-CRM patients (p > 0.05). Data presented here demonstrate for the first time that neoadjuvant CTx significantly impairs hypertrophy of the FLR after ALPPS.
- 11 December 2014
- Published by Georg Thieme Verlag KG in Gastroenterologie up2date
- Vol. 10 (04) , 229-230
Mixed adenoneuroendokrines Karzinom (MANEC) des rektosigmoidalen Überganges
MANEC-Tumoren stellen eine extrem seltene Form bösartiger kolorektaler Tumoren dar. Die interdisziplinäre Behandlung und Nachsorge dieser Patienten sollte in spezialisierten Tumorzentren mit entsprechender Expertise stattfinden. Die Behandlung orientiert sich an der aggressiveren Komponente des Tumors und richtet sich chirurgischerseits nach den allgemeinen Prinzipien der onkologischen Chirurgie, insbesondere der kolorektalen Chirurgie.
- 11 December 2014
- Published by Georg Thieme Verlag KG in Gastroenterologie up2date
- Vol. 10 (04) , 229-230
Mixed adenoneuroendokrines Karzinom (MANEC) des rektosigmoidalen Überganges
MANEC-Tumoren stellen eine extrem seltene Form bösartiger kolorektaler Tumoren dar. Die interdisziplinäre Behandlung und Nachsorge dieser Patienten sollte in spezialisierten Tumorzentren mit entsprechender Expertise stattfinden. Die Behandlung orientiert sich an der aggressiveren Komponente des Tumors und richtet sich chirurgischerseits nach den allgemeinen Prinzipien der onkologischen Chirurgie, insbesondere der kolorektalen Chirurgie.
- 11 December 2014
- Published by Georg Thieme Verlag KG in Gastroenterologie up2date
- Vol. 10 (04) , 224-228
Mixed adenoneuroendokrines Karzinom (MANEC) des rektosigmoidalen Überganges
1 Institut für Pathologie, Universitätsklinikum Carl Gustav Carus Dresden, TU Dresden 2 Institut und Poliklinik für Radiologische Diagnostik, Universitätsklinikum Carl Gustav Carus Dresden, TU Dresden 3 Klinik und Poliklinik für Viszeral-, Thorax- und Gefäßchirurgie, Universitätsklinikum Carl Gustav Carus Dresden, TU Dresden 4 Medizinische Klinik I, Universitätsklinikum Carl Gustav Carus Dresden, TU Dresden
- 11 December 2014
- Published by Georg Thieme Verlag KG in Gastroenterologie up2date
- Vol. 10 (04) , 224-228
Mixed adenoneuroendokrines Karzinom (MANEC) des rektosigmoidalen Überganges
1 Institut für Pathologie, Universitätsklinikum Carl Gustav Carus Dresden, TU Dresden 2 Institut und Poliklinik für Radiologische Diagnostik, Universitätsklinikum Carl Gustav Carus Dresden, TU Dresden 3 Klinik und Poliklinik für Viszeral-, Thorax- und Gefäßchirurgie, Universitätsklinikum Carl Gustav Carus Dresden, TU Dresden 4 Medizinische Klinik I, Universitätsklinikum Carl Gustav Carus Dresden, TU Dresden
- Open Access
- 18 January 2013
- Published by Springer Nature
Perioperative management of antiplatelet agents in general and visceral surgery: a pilot study
- 18 January 2013
- Published by Springer Nature
Open AccessPerioperative management of antiplatelet agents in general and visceral surgery: a pilot study
- Open Access
- 11 December 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 592
Intraoperative Electron Radiation Therapy (IOERT) in the management of locally recurrent rectal cancer
To evaluate disease control, overall survival and prognostic factors in patients with locally recurrent rectal cancer after IOERT-containing multimodal therapy.
- 11 December 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 592
Open AccessIntraoperative Electron Radiation Therapy (IOERT) in the management of locally recurrent rectal cancer
To evaluate disease control, overall survival and prognostic factors in patients with locally recurrent rectal cancer after IOERT-containing multimodal therapy.
- Open Access
- 20 August 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 361
Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer
Background: The investigational oral DNA vaccine VXM01 targets the vascular endothelial growth factor receptor 2 (VEGFR-2) and uses Salmonella typhi Ty21a as a vector. The immune reaction elicited by VXM01 is expected to disrupt the tumor neovasculature and, consequently, inhibit tumor growth. VXM01 potentially combines the advantages of anti-angiogenic therapy and active immunotherapy. Methods/Design: This phase I trial examines the safety, tolerability, and immunological and clinical responses to VXM01. The randomized, placebo-controlled, double blind dose-escalation study includes up to 45 patients with locally advanced and stage IV pancreatic cancer. The patients will receive four doses of VXM01 or placebo in addition to gemcitabine as standard of care. Doses from 106 cfu up to 1010 cfu of VXM01 will be evaluated in the study. An independent data safety monitoring board (DSMB) will be involved in the dose-escalation decisions. In addition to safety as primary endpoint, the VXM01-specific immune reaction, as well as clinical response parameters will be evaluated. Discussion: The results of this study shall provide the first data regarding the safety and immunogenicity of the oral anti-VEGFR-2 vaccine VXM01 in cancer patients. They will also define the recommended dose for phase II and provide the basis for further clinical evaluation, which may also include additional cancer indications. Trial registration: EudraCT No.: 2011-000222-29, NCT01486329, ISRCTN68809279
- 20 August 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 361
Open AccessDouble-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer
Background: The investigational oral DNA vaccine VXM01 targets the vascular endothelial growth factor receptor 2 (VEGFR-2) and uses Salmonella typhi Ty21a as a vector. The immune reaction elicited by VXM01 is expected to disrupt the tumor neovasculature and, consequently, inhibit tumor growth. VXM01 potentially combines the advantages of anti-angiogenic therapy and active immunotherapy. Methods/Design: This phase I trial examines the safety, tolerability, and immunological and clinical responses to VXM01. The randomized, placebo-controlled, double blind dose-escalation study includes up to 45 patients with locally advanced and stage IV pancreatic cancer. The patients will receive four doses of VXM01 or placebo in addition to gemcitabine as standard of care. Doses from 106 cfu up to 1010 cfu of VXM01 will be evaluated in the study. An independent data safety monitoring board (DSMB) will be involved in the dose-escalation decisions. In addition to safety as primary endpoint, the VXM01-specific immune reaction, as well as clinical response parameters will be evaluated. Discussion: The results of this study shall provide the first data regarding the safety and immunogenicity of the oral anti-VEGFR-2 vaccine VXM01 in cancer patients. They will also define the recommended dose for phase II and provide the basis for further clinical evaluation, which may also include additional cancer indications. Trial registration: EudraCT No.: 2011-000222-29, NCT01486329, ISRCTN68809279